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Abstract
Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer with short overall survival. Long
non-coding RNAs (lncRNA) are a class of RNAs more than 200 nucleotides long that do not code for protein and
are part of the 90% of the human genome that is transcribed. Earlier experimental studies in mice showed GAS5
(growth arrest specific transcript 5) gene deletion in asbestos driven mesothelioma. GAS5 encodes for a lncRNA
whose function is not well known, but it has been shown to act as glucocorticoid receptor decoy and microRNA
“sponge”. Our aim was to investigate the possible role of the GAS5 in the growth of MPM.
Methods: Primary MPM cultures grown in serum-free condition in 3% oxygen or MPM cell lines grown in
serum-containing medium were used to investigate the modulation of GAS5 by growth arrest after inhibition of
Hedgehog or PI3K/mTOR signalling. Cell cycle length was determined by EdU incorporation assay in doxycycline
inducible short hairpinGAS5 clones generated from ZL55SPT cells. Gene expression was quantified by quantitative
PCR. To investigate the GAS5 promoter, a 0.77 kb sequence was inserted into a pGL3 reporter vector and luciferase
activity was determined after transfection into MPM cells. Localization of GAS5 lncRNA was identified by in situ
hybridization. To characterize cells expressing GAS5, expression of podoplanin and Ki-67 was assessed by
immunohistochemistry.
Results: GAS5 expression was lower in MPM cell lines compared to normal mesothelial cells. GAS5 was upregulated
upon growth arrest induced by inhibition of Hedgehog and PI3K/mTOR signalling in in vitro MPM models. The increase
in GAS5 lncRNA was accompanied by increased promoter activity. Silencing of GAS5 increased the expression of
glucocorticoid responsive genes glucocorticoid inducible leucine-zipper and serum/glucocorticoid-regulated kinase-1
and shortened the length of the cell cycle. Drug induced growth arrest was associated with GAS5 accumulation in the
nuclei. GAS5 was abundant in tumoral quiescent cells and it was correlated to podoplanin expression.
Conclusions: The observations that GAS5 levels modify cell proliferation in vitro, and that GAS5 expression in MPM
tissue is associated with cell quiescence and podoplanin expression support a role of GAS5 in MPM biology.
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Background
Malignant pleural mesothelioma (MPM) are tumors ori-
ginating from the surface serosal cells of the pleura [1].
MPM are rare tumors mainly caused by exposure to as-
bestos and patients have a median survival around
12 months even after combined chemotherapy [2,3].
Molecular studies identified altered expression of critical
genes in oncogenesis, especially tumor suppressor genes
at the INK4 and NF2 loci (reviewed in [4]). A recent study
has shown dysregulation of long non-coding RNA
(lncRNA) expression in MPM compared to normal meso-
thelium [5]. LncRNA are part of the transcriptome that
does not encode for proteins, which includes tens of thou-
sands of lncRNA [6]. LncRNAs are defined as being
longer than 200 nucleotides [7] and have poor sequence
conservation across species [8] which led to the hypoth-
esis that the function is most likely linked to the RNA
structure itself. The functions of some lncRNAs have been
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described and include chromatin modifier, transcriptional
and post-transcriptional regulator of gene expression
[9-11]. In this context, lncRNAs are now emerging as
mammalian transcription key regulators in response to
developmental or environmental signals [12-14] and are
associated to many cancer related pathways through gene
regulation [15]. Although much has still to be investigated
about the major part of lncRNAs, the involvement of
some of them in tumor progression has already been
shown, e.g. lncRNA HOTAIR which interacts with the
chromatin-remodelling complex PRC2 [16].
Interestingly, a minimal region of deletion was identified
in asbestos induced murine malignant mesothelioma which
includes gas5 locus [17]. The GAS5 gene is a so-called host
gene for small nucleolar RNA (snoRNA) and it is encoded
at locus 1q25. It has up to 12 exons and 10 box C/D snoR-
NAs within its alternative introns together with conserved
5′-terminal oligopyrimidine tract (5′ TOP) [18]. GAS5 is
named based on the finding that its expression levels in-
creased upon cell growth arrest induced after serum starva-
tion [19] or as the result of rapamycin-induced cell cycle
arrest [18]. Recent studies have shown that GAS5 silencing
in T cells increased the proportion of cells in S phase, re-
duced the rate of spontaneous apoptosis [20] and protected
cells from rapalogue (temsirolimus, everolimus) induced
proliferation arrest [21]. In epithelial cells GAS5 regulates
glucocorticoid-dependent transcription by acting as a decoy
outcompeting the DNA-binding site of the glucocorticoid
receptor, thereby reducing cell metabolism [22]. More re-
cently GAS5 has been described to act as sponge which
sequesters miR-21 [23]. GAS5 is also part of lncRNA abun-
dantly expressed in cancer cells [24]. In this study, we in-
vestigate whether GAS5 has a role in MPM biology.
Results
GAS5 lncRNA expression level is lower in MPM cell lines
compared to normal mesothelial cells and it is increased
by drugs inducing growth arrest
GAS5 expression in MPM cell lines (n = 22) is signifi-
cantly lower (Figure 1A; p < 0.005; individual MPM cell
line profile is shown Additional file 1: Figure S1) when
compared to normal mesothelial cells (n = 7). The GAS5
gene produces 29 different splice variants (Additional
file 2: Table S1) including 10 processed lncRNAs con-
taining or not one or more snoRNA sequences, and 19
unprocessed sequences. The only information available
on splice variants expressed in experimental models is
provided by one study, where the expression of both
mature and unprocessed GAS5 was observed in phyto-
haemagglutinin stimulated primary lymphocytes [20]. In
order to investigate which splice variant is expressed in
MPM, we used two sets of primers, theoretically allow-
ing the detection of 20 different cDNAs of GAS5 splice
variants (Additional file 3: Table S2) to amplify GAS5
cDNA from four mesothelioma cell lines (ZL55SPT,
SDM103T2, ZL55 and ACC-Meso4) that had been se-
lected for functional studies. According to the size of PCR
fragments observed for each primer set (Additional file 4:
Figure S2) and taking into account the detection by the
two primer sets, the list of cDNA expressed was narrowed
down to three splice variants including two lncRNA and
one intron retaining transcript (Table 1). The expression
of the intron retaining transcript was further confirmed
using specific primers (Additional file 4: Figure S2D).
Quantitative abundance of the different transcripts varied
depending on the cell line (Additional file 4: Figure S2B, C
and D). To investigate whether GAS5 expression in MPM
cells could be modulated by drugs inducing growth arrest,
we treated MPM cells with either HhAntag or with NVP-
BEZ235 as previously described [25,26]. ZL55SPT and
SDM103T2 cells, grown in serum-free medium and at 3%
of oxygen conditions, which allow maintenance of dedif-
ferentiation properties [25], where treated during 48 h
with HhAntag. A significant (p < 0.05) increase of GAS5
lncRNA levels (Figure 1B) and of the number of quiescent,
ki67 negative (G0) cells (Additional file 5: Figure S3) was
observed compared to control. Similar results were ob-
served by treating ZL55 and ACC-Meso4 cells, which are
grown in serum-containing medium, during 6 h with
GI50 (Echeverry, ms in preparation) concentration of
NVP-BEZ235 (Figure 1C). While it is not possible to
investigate the effect of HhAntag in cell grown in serum
containing medium [25], a significant increase of GAS5
levels was observed after treatment of ZL55SPT and
SDM103T2 to NVP-BEZ235 (Additional file 6: Figure S4),
indicating that cells grown in dedifferentiating conditions
remain sensitive to this drug.
To investigate whether increased GAS5 RNA levels ob-
served after treatment with HhAntag and NVP-BEZ235
were associated with increased GAS5 promoter activity, we
transfected ZL55SPT and ZL55 cells with a luciferase
reporter gene under the control of GAS5 promoter
sequences (pGL3-B-pGAS5). Luciferase activity was mea-
sured 24 hours after growth arrest-inducing treatment. Al-
though basal pGL3-B-pGAS5 was very high (approximately
a thousand fold higher than empty vector, data not shown),
a dose dependent significant (p < 0.05) increase in promoter
activity was identified in ZL55SPT and ZL55 cells
after HhAntag and NVP-BEZ-235 treatment (Figure 1D),
respectively. Altogether, these results suggest that GAS5
may participate to the growth inhibitory action of HhAntag
and NVP-BEZ235 in MPM cells.
Silencing of GAS5 in MPM cells increases glucocorticoid
receptor responsive genes and shortens the cell cycle length
To investigate whether GAS5 plays a role in MPM growth,
stable doxycycline-inducible shRNA-GAS5 clones were
generated using ZL55SPT cells. GAS5 expression levels
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decreased in a doxycycline dose-dependent manner in
shGAS5-1 and shGAS5-2 while it was not affected in con-
trol cells (Figure 2A). The partial resistance to siRNA-
mediated knockdown is consistent with what has been re-
cently described [27] for nuclear lncRNA (see below). To
determine whether the observed 35 and 25% (in shGAS-1
and shGAS5-2, respectively) decrease in GAS5 expression
was functionally relevant, we determined the consequences
on glucocorticoid regulated genes such as glucocorticoid in-
ducible leucine-zipper (GILZ) and serum/glucocorticoid-
regulated kinase-1 (SGK1). Indeed, GAS5 lncRNA functions
as a decoy for glucocorticoid receptor [22]. As ZL55SPT
cells are grown in a serum-free medium containing pharma-
cological concentrations of glucocorticoids, which are essen-
tial for optimal cell growth [25,28], we expected that
modulation of GAS5 levels would modify the expression of
glucocorticoid regulated genes. Accordingly, we observed
that doxycycline-induced decrease of GAS5 expression in
shGAS5 clones was accompanied by a significant increase
of expression of GILZ in shGAS5-2 clone (Figure 2B) and
of SGK1 in shGAS5-1 clone (Figure 2C) while no change
was observed in sh control clone, indicating a negative role
of GAS5 in the expression of these genes. These observa-
tions were confirmed using three independent GAS5
siRNA. Indeed, we observed a significant down-regulation
of GAS5 accompanied by a significant increase of GILZ
mRNA for the three siRNA tested compared to a control
siRNA and a significant increase of SGK1 mRNA for two of
the three tested siRNA (Additional file 7: Figure S5).
Next we determined whether GAS5 knockdown affects
cell cycle. In order to measure cell cycle length, we per-
formed a time course experiment after pulse labelling
shGAS5-1 and shGAS-2 cells with 5-ethynyl-2′-deoxyuri-
dine (EdU). EdU assay revealed an increase in EdU positive
cells after doxycycline-induced silencing of GAS5 in
shGAS5 clones (Figure 3A and B) while no effect was ob-
served in control cells (data not shown). Using a linear re-
gression method [29], we determined the time taken for
100% EdU incorporation, which corresponds to the time
needed for single cell cycle length (Figure 3B). The cell cycle
length of uninduced shGAS5 clones was 55–77 hours while
the GAS5 silenced cells exhibited a shorter cell cycle of 40
to 47 hours (Figure 3C). Collectively these results confirm
that silencing GAS5 has functional consequences in the
growth of MPM cells grown in serum-free conditions.
HhAntag-induced growth arrest is accompanied by GAS5
accumulation into the nuclei
To further characterize the mechanism of GAS5 in con-
trolling cell growth in serum-free conditions, we analysed
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Figure 1 GAS5 expression is lower in MPM and it is increased upon drug induced growth arrest. A. GAS5 is lower in MPM cell lines compared to
normal mesothelial cell lines. GAS5 lncRNA expression was analysed by qRT-PCR in 22 MPM cell lines and in 7 normal mesothelial cell lines. Expression of
GAS5 was normalized to internal control histones relative to the mean expression of GAS5 in normal mesothelial cells in culture according to –ΔΔCt
method. B and C. Drug induced growth arrest increases GAS5 expression in MPM primary cells (ZL55SPT and SDM103T2) and cell lines (ZL55 and
ACC-Meso4). D. Expression of GAS5 promoter reporter gene was analysed in control versus HhAntag and NVP-BEZ235 treated samples. Promoter activity,
expressed as relative light unit (RLU) normalized to control set at 100%, is significantly increased by treatment with HhAntag and NVP-BEZ235. Values are
expressed as mean ± SD from three independent experiments *; p < 0.05.
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the subcellular localization of GAS5 after treatment with
HhAntag by in situ hybridization. We confirmed a dose-
dependent significant (p < 0.05) increase in GAS5 accu-
mulation in the cells and observed an enrichment into the
nucleus (Figure 4A and B). Quantification revealed that
GAS5 is twice as abundant in the nucleus as in the cytosol
in the absence of HhAntag and prevalence in the nucleus
was maintained after treatment with HhAntag (Figure 4C).
Altogether, these data indicate that HhAntag-induced
growth arrest involves accumulation of nuclear GAS5.
Podoplanin expression correlates with GAS5 in malignant
pleural mesothelioma
In order to determine the relevance of our in vitro find-
ings in clinical samples we determined GAS5 relative ex-
pression in MPM and normal tissue. Surprisingly, we
found a significant six-fold (p < 0.0001) increase of GAS5
level in tumor tissue (n = 116) when compared to non-
tumoral samples (n = 10) (Additional file 8: Figure S6A).
This was unexpected considering the upregulation GAS5
during growth arrest and the shortening of cell-cycle
observed upon GAS5 silencing. Because MPM tissue con-
tains stromal cells [30] including immune system cells that
are highly enriched for GAS5 expression [21], we per-
formed in situ hybridization in a subset of samples to
investigate and characterize the cells expressing GAS5.
GAS5 expression was predominantly identified in quies-
cent tumor cells (Figure 5A). To further characterize
GAS5 expression in relationship to MPM tumors we
therefore investigated the relationship of GAS5 expression
with mesothelial markers such as mesothelin, calretinin
and podoplanin extending a previous analysis of these
markers performed on a limited set of samples [30]. Hier-
archical clustering of these mesothelial markers with GAS5
showed that the expression of GAS5 clustered with podo-
planin in epithelioid, biphasic and sarcomatoid tissue sam-
ples (Figure 5B) and a positive correlation between GAS5
and podoplanin levels (p < 0.05) was observed (Figure 5C).
Furthermore, GAS5 expression was higher in samples with
high podoplanin (D2-40) expression (Figure 5A and
Additional file 8: Figure S6B). No correlation was observed
between GAS5 and mesothelin or calretinin.
Overall, these results indicate that in vivo GAS5 expres-
sion may play a role not only in growth control but may
have additional functions such as the already described
miRNA sponge activity [23].
Discussion
In this study we revealed the functional consequences of
the expression of GAS5, a lncRNA abundantly expressed
in MPM. When compared to normal mesothelial cells,
MPM cell lines expressed lower levels of GAS5 and expos-
ure to drugs inducing growth arrest increased GAS5 ex-
pression level, in line with what had been previously
described with rapamycin-induced cell cycle arrest of
NIH3T3 cells [18]. We identified that increased GAS5
levels were associated to increased promoter activity. This
is important since it has been shown that GAS5, as other
mRNAs carrying 5’ TOP, can be stabilized by interaction
with La motif-related protein 1 [31]. Interestingly, basal
levels of GAS5 promoter were quite high. The promoter is
likely to be bidirectional (Additional file 9: Figure S7) con-
trolling both GAS5 and zinc finger and BTB domain
containing 37 (ZBTB37). Not much is known about
ZBTB37 except that it is a transcription factor known to
be expressed during embryonic development [32]. It
might be interesting to verify whether ZBTB37 is
expressed in MPM after that the mechanisms of induction
of GAS5 promoter have been elucidated.
GAS5 plays an essential role in growth arrest state of
both T-cell lines and non-transformed lymphocytes [21].
Table 1 List of GAS5 alternative splice variants
corresponding to the size of RT-PCR products
Vega Genome Browser 54
Transcript ID
Length
(bp)
Type
GAS5-Ex-4-8
207 bps
OTTHUMT00000090577 632 LncRNA
OTTHUMT00000090578 1698 Retained
Intron
OTTHUMT00000090585 632 Retained
Intron
OTTHUMT00000090586 712 Retained
Intron
OTTHUMT00000090590 688 LncRNA
OTTHUMT00000090593 772 Retained
Intron
OTTHUMT00000090598 979 Retained
Intron
168 bps
OTTHUMT00000090579 565 LncRNA
OTTHUMT00000090595 745 Retained
Intron
OTTHUMT00000090597 497 Retained
Intron
OTTHUMT00000090605 723 Retained
Intron
GAS5-Ex-6-12
281 bps
OTTHUMT00000090577 632 LncRNA
OTTHUMT00000090586 712 Retained
Intron
OTTHUMT00000090590 688 LncRNA
242 bps
OTTHUMT00000090579 565 LncRNA
OTTHUMT00000090584 542 LncRNA
OTTHUMT00000090604 413 LncRNA
Transcripts that were detected by both primer sets are in bold.
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Silencing of GAS5 resulted in shortening cell cycle in MPM
cells demonstrating that also in these cells GAS5 controls
cell growth. The underlying mechanism can be linked to
the fact that GAS5 is a glucocorticoid receptor-decoy and it
inhibits transcription of glucocorticoid responsive genes
[22]. Glucocorticoids are essential for optimal MPM cell
growth [25,28] and are present at pharmacological concen-
trations in culture medium [33,34]. We estimated that
GAS5 is present at the level of ten thousand copies/cell,
which is in the range of the reported abundancy of gluco-
corticoid receptors [35-37]. Therefore it is not surprising
that under our experimental conditions a change of
glucocorticoid-regulated genes was observed upon GAS5
silencing. Quantitative in situ hybridization allowed deter-
mining that two thirds of GAS5 is present in the nucleus.
Assuming that 10% of total cellular volume is occupied by
nucleus this means that nuclear GAS5 concentration is ap-
proximately 18 fold higher in the nuclei compared to the
cytosol. It had already been shown that GAS5 is located
both in cytoplasm and the nucleus and translocates from
the cytoplasm into the nucleus with glucocorticoid receptor
in response to dexamethasone [22] but quantitative data
were not available. Because there are cell to cell variations
in the nuclear abundancy of GAS5 and 35% of cells are in
quiescent state, it is tempting to speculate that cells with
high nuclear levels of GAS5 are quiescent cells. Although
we could not address this question in cultured cells, since
in situ hybridization of nuclear RNA is not compatible with
e.g. Ki-67 immunohistochemistry within the same speci-
men, we observed in MPM tumors that GAS5 expressing
tumor cells were Ki-67 negative supporting the idea of
nuclear GAS5 being associated with growth arrest. Besides
interference with glucocorticoids signalling, other mecha-
nisms may involve chromatin remodelling, since GAS5
expression is increased after growth arrest induced by silen-
cing of Brahma ATPase subunit of mammalian SWI/SNF
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Figure 2 Silencing of GAS5 increases glucocorticoid responsive genes. A. GAS5 lncRNA silencing increases the expression of glucocorticoid
responsive genes GILZ (B) and SGK1 (C). Values are normalized with histones and shown as mean ± SD from three to four independent experiments.
*; p < 0.05.
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complexes [29]. The latter are a family of chromatin re-
modeling enzymes that regulate gene expression by disrupt-
ing histone-DNA contacts in an ATP-dependent manner.
After drug treatment inducing growth arrest GAS5
levels were higher. Interestingly, genome-wide data on
RNA and protein quantities in proliferating vs. quiescent
yeast cells has revealed that although the proteome size is
similar in proliferating and quiescent cells, the transcrip-
tome is decreased to 20% in quiescent compared to prolif-
erating cells [38], indicating that the increase in GAS5
levels observed upon drug treatment inducing cell-cycle
arrest are probably underestimated in the context of
whole transcriptome.
GAS5 was mostly accumulating in the nucleus after
growth arrest induced by HhAntag, suggesting that the
control of cell cycle is dependent on nuclear GAS5.
Control of cell cycle mediated by lncRNA has been demon-
strated for MALAT1, whereby silencing MALAT1 resulted
in decreased proliferation because MALAT1 is required for
mitotic progression [39] during which MALAT1 migrated
from the nucleus to the cytoplasm shuttling heterogeneous
ribonucleoprotein C, which is necessary to increase IRES-
dependent translation of c-myc [40]. Altogether, these data
support that nuclear-cytoplasmic shuttling of lncRNA is
tightly regulated by mechanism controlling cell cycle.
Surprisingly, GAS5 was expressed at higher level in
tumor tissue compared to non-tumoral tissue. This in
contradiction with other tumor tissues such as breast [41],
bladder [42] and pancreatic [43] cancer where GAS5
expression was lower in tumor compared to non-tumoral
tissue. One reason might be that primers recognizing all
GAS5 ESTs were used in the breast cancer study [41],
while in our case primers were recognizing only 20 out of
29 different splice variants, which nevertheless included
the splice variants detected in cancer cells. In the other
two studies primer sequence was not specified so the
comparison is not possible. Another explanation for this
discrepancy could have been that GAS5 expression seems
tissue-dependent, accordingly to publicly available inte-
grated database on transcriptome [44]. Therefore, a high
expression in tumoral tissue could have resulted from e.g.
lymphocytes infiltration. By in situ hybridization of MPM
tissue we observed a high GAS5 expression in quiescent
tumor cells. In order to find an explanation why GAS5
expression should be high in tumor cells, we compared
GAS5 expression to known mesothelioma markers and
found that GAS5 expression was positively correlated to
podoplanin expression. The latter is a type I transmem-
brane sialomucin-like glycoprotein, which induces platelet
aggregation and which is highly expressed in malignant
pleural mesothelioma [45]. Due to the coincidence of
GAS5 expression with podoplanin immunoreactivity and
the fact that GAS5 has been recently demonstrated to
have miRNA sponge activity [23] one possibility is that
high GAS5 expression is not only controlling cell cycle,
but it is acting as miRNA natural sponge [46] to scavenge
podoplanin mRNA degradation by miRNA, which is
known to occur at least in glioblastoma [47]. Further work
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is necessary to investigate this hypothesis, nevertheless se-
quence analysis revealed shared miRNA target sequence
in GAS5 and podoplanin (http://www.mircode.org).
Conclusions
In conclusion, accumulating evidences shows that lnc
RNAs have a definitive role in carcinogenesis, invasion
and metastasis [15,48]. Our experiments demonstrate that
GAS5 expression plays a role in MPM biology.
Methods
Tumor specimens
Tumor specimens were obtained for diagnostic purpose
before chemotherapy or at the time of resection and were
immediately processed as previously described for total
RNA extraction using Qiagen RNAeasy® and cDNAs was
prepared from 400–500 ng of RNA (Qiagen QuantiTect®
Reverse Transcription protocol) [30]. In addition, parts of
tumor specimens were fixed in paraformaldehyde for par-
affin embedding. Normal pleural tissue was received from
ten patients undergoing mesothelioma unrelated thoracic
surgery. The study was approved by the Zurich University
Hospital ethic committee and a written informed consent
was obtained from all patients.
Cell culture and drug treatment
Primary MPM cultures were established from surgical
specimens and maintained with serum and without serum
as previously described [25,49]. MPM cells-SPC111,
SPC212, ZL34 and ZL55, were established in our labora-
tory [50] and were maintained in DMEM:F12 (Ham)
medium (Sigma-Aldrich, St. Louis, MO, USA) with 15%
foetal calf serum (FCS, Invitrogen/GIBCO) and 1% peni-
cillin/streptomycin (Sigma-Aldrich); Mero- 14, Mero-41,
Mero-48, Mero-82, Mero-83, Mero-84 and Mero-95 were
maintained in DMEM:F10 (Ham) medium (Sigma-
Aldrich) with 15% FCS and 1% penicillin/streptomycin;
ONE-58, ACC-Meso-1 and ACC-Meso-4 were main-
tained in RPMI-1640 (Sigma-Aldrich) with 15% FCS and
1% penicillin/streptomycin; MSTO-211H, H2052, H2452,
H226, NO36 and H596 cells were maintained in RPMI-
1640 with 10% FCS and 1% penicillin/streptomycin.
ZL55SPT and SDM103T2 primary cells were grown in
serum-free medium [25]. Normal mesothelial cells NP3,
SDM77, SDM85, SDM104, SDM58 and SDM71 were
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cultured as previously described [51]. NP3 cells were also
grown in serum-free medium. To induce growth arrest,
cells were treated either with Hedgehog signaling inhibitor
(HhAntag) [25] or with dual PI3K/mTOR inhibitor (NVP-
BEZ235, Novartis, Switzerland) [26], as previously des
cribed.
Gene expression
Selected gene expression analysis using MIQE [52] com-
pliant protocols was conducted as previously described
[30]. Briefly, cDNA was amplified by the SYBR-Green
PCR assay and products were detected on a 7900HT Fast
real-Time PCR system (SDS, ABI/Perkin Elmer). Relative
mRNA levels were determined by comparing the PCR cycle
thresholds between cDNA of a specific gene and histone
(ΔCt). The 5′ and 3′ primers for GAS5 - AAGCCATTGG
CACACAGGCATTAG and AGAACCATTAAGCTGGTC
CAGGCA, glucocorticoid-induced leucine zipper protein
(GILZ) [22] – AACAGGCCATGGATCTGGTGAAGA and
AGGGTCTTCAACAGGGTGTTCTCA, serum/glucocorti
coid-regulated kinase 1 (SGK1) - CTATGCTGCTGAAATA
GC and GTCCGAAGTCAGTAAGG, respectively. RNA
extraction and cDNA preparation from cell cultures was
achieved as detailed for tumor samples. The heatmap of ex-
pression level of GAS5, mesothelin, calretinin and podopla-
nin was produced as previously described [30,49].
Control GAS5 Ki67
Control D2-40 H&E
A)
m
57
m
24
1
m
20
6
m
13
7
m
14
8
m
18
1
m
55
m
18
9
m
59
m
19
1
m
22
0
m
22
4
m
22
5
m
20
7
m
21
9
m
23
9
m
16
5
m
17
1
m
20
5
m
12
0
m
12
8
m
68
 
m
12
6
m
83
m
18
7
m
24
2
m
76
m
23
3
m
18
2
m
18
3
m
13
2 
m
20
2
m
13
3
m
13
0
m
17
3
m
13
4
m
18
0
m
22
3
m
21
6
m
22
9
m
11
5
m
60
m
53
m
12
5
m
22
6
m
17
6
m
91
m
87
m
13
6
m
14
1
m
14
5
m
11
2
m
23
0
m
14
3
m
86
m
15
4
m
17
9
m
22
2
m
18
8
m
10
6
m
16
8
m
17
2
m
12
4
m
24
7
m
11
0
m
16
6
m
16
1
m
24
5
m
15
8
m
16
9
m
15
9
m
14
4
m
72
m
13
8
m
14
2
m
96
m
24
6
m
13
9
m
22
8
m
20
4
m
61
m
14
0
m
16
7
m
23
8
m
17
7
m
21
1
m
97
m
22
7
m
15
2
m
15
6
m
19
8
m
24
4
m
24
3
m
20
0
m
93
m
21
4
m
23
2
Mesothelin
Calretinin
PDPN
GAS5
-4.72 -1.12 -0.18 0.63 8.38
Epitheliod
m
19
5
m
17
8
m
15
5
m
19
3
m
23
1
m
20
9
m
78
m
19
9
m
67
m
12
7
m
15
7
m
10
7
m
54 m
80
Mesothelin
Calretinin
PDPN
GAS5
Biphasic
-1.64 -0.33 0.49 1.72 9.76
Sarcomatoid
Mesothelin
Calretinin
PDPN
GAS5
m
20
1
m
10
1
m
10
5
m
81
m
14
7
-1.80 -1.10 0.63 5.21 10.58
B)
C)
R
el
at
iv
e 
G
A
S
5 
ln
cR
N
A
 le
ve
l (
-Δ
Δ
C
t)
PDPN High PDPN Low
-2
0
2
4
6
8 *
Figure 5 GAS5 expression is higher in podoplanin positive MPM tumor cells. A. Fluorescence in situ hybridization and immunohistochemical
analysis of GAS5, Ki-67 and podoplanin in a representative patient. Upper panel shows fluorescence in situ hybridization of control and GAS5,
immunostaining of Ki-67 (ab15580, Abcam). Lower panel shows the immunostaining of control and podoplanin (D2-40, DAKOCytomation) and
hematoxylin and eosin stained tumor tissue. Scale bar: 50 μm. B. Matrix of relative gene expression in epitheliod, biphasic and sarcomatoid mesothelioma
shown as heat map. Heat map is a grid of rectangles with colors that indicate the value of the matrix elements, where high expression is blue and low
expression is red. Rows of each heat map correspond to genes, whilst columns correspond to MPM tumor samples. C. GAS5 expression is higher in MPM
tissue expressing higher levels of podoplanin *p < 0.05, Mann–Whitney test.
Renganathan et al. Molecular Cancer 2014, 13:119 Page 8 of 12
http://www.molecular-cancer.com/content/13/1/119
Plasmid constructs
To investigate the role of GAS5 on cell growth we have
generated a system, which allows inducing the silencing of
GAS5 by the addition of doxycycline. The shRNA se-
quence against GAS5 is based on published results [22].
The template for shRNA expression has been obtained by
annealing oligonucleotides (GATCCCC CTTGCCTGGA
CCAGCTTAA TTCAAGAGA TTAAGCTGGTCCAGG
CAAG TTTTTA and AGCTTAAAAA CTTGCCTGGAC
CAGCTTAA TCTCTTGAA TTAAGCTGGTCCAGGCA
AG GGG). The sense and antisense strands of the 19-
nucleotide (nt) which targets nucleotides 199 to 217 of the
human GAS5 sequence (GenBank accession number
NR_002578) are indicated in italics and are separated by a
9-nt loop sequence (TTCAAGAGA). For the negative
control a scrambled sequence was used [22,53]. These 60-
base long oligonucleotides containing the coding and
complementary sequence of these components, together
with BglII and HindIII restriction site sequences at the 5′
and 3′ ends respectively, have been annealed and ligated
into pSUPERIOR. PURO vector digested with BglII and
HindIII restriction sites. The construct has been checked
by DNA sequencing and was deposited in Addgene
repository (46370, pSuperior-sh-GAS5).
Stable doxycycline-inducible shGAS5 and sh control
clones have been generated by co-transfection of the indu-
cible shGAS5 or control constructs with the plasmid
pcDNA6/TR (Invitrogen), encoding high levels of the
tetracycline repressor, in human MPM ZL55SPT cells
grown in the absence of serum using Lipofectamine 2000
(Invitrogen). After selection with puromycin (0.4 μg/ml)
and blasticidin (2.5 μg/ml), stable clones have been iso-
lated. Optimal dose and time for doxycycline to induce si-
lencing of GAS5 was obtained as 0.1 and 0.5 μg/ml for
72 hrs (refreshing doxycycline after 48 hrs). Under these
conditions no cell growth alteration, assessed by MTT cell
viability assay, was observed in parental ZL55SPT cells.
To investigate the control of GAS5 transcription,
771 bp upstream GAS5 transcription starting site was
amplified using the following primers with NheI and
HindIII restriction sites:
5′- ACGTGCTAGCTCAGGTGAGAACTAGGAAGG −3′
and
5′- ACGTAAGCTTAAGACAGTATGGTGCCTGGG −3′
and subcloned into pGL3 luciferase reporter (pGL3-B-
pGAS5, Addgene 46371).
RNA interference by siRNA
For down-regulation of GAS5 with small interfering RNAs
(siRNA), ZL55SPT cells were transfected with 25 nM Qia-
gen siRNAs targeting GAS5: siGAS5_1 FlexiTube siRNA
(targeting exon 11), siGAS5_2 FlexiTube siRNA (targeting
exon 3), siGAS5_4 FlexiTube siRNA (targeting exons 10–
11) or control non targeting (NT) siRNA (Thermo Scien-
tific Dharmacon), according to the manufacturer’s reverse
transfection protocol as previously described [25]. Cells
were then plated at 7000 cells/cm2 and RNA was ex-
tracted after 72 h.
GAS5 promoter reporter assays
To confirm upregulation of GAS5 transcription upon
treatment inducing growth arrest dual luciferase assay was
used. Briefly, pGL3-B-pGAS5 was transfected together
with Renilla Luciferase (50:1) in cells seeded in 12 wells
(40’000-100’000 cells/well) as previously described [25].
After 24 h, transfected cells were either treated with
HhAntag, NVP-BEZ235 or vehicle for 24 h then were
lysed and analyzed using Dual-Luciferase reporter assay
system according to manufacturer instruction (Promega,
Madison, Wi, USA).
Analysis of GAS5 splice variants
To identify which GAS5 splice variant is expressed in cell
lines that were used in functional assays, we designed
three primers sets. PCR reaction was carried out with the
following conditions: initial denaturation at 94°C 5 min,
then 35 cycles at 95°C 1 min, annealing at 55°C 1 min;
and extension at 72°C 2 min. Primer sequences were:
GAS5-Ex-4-8-F,- 5′-GTCCTAAAGAGCAAGCCTAACT-
3′ and GAS5-Ex-4-8-R,- 5′-TAGTCAAGCCGACTCTC
CATA-3′, GAS5-Ex-6-12-F,- 5′-TAATGGTTCTGCTCC
TGGTAAC-3′ and GAS5-Ex-4-8-R,- 5′-CAAAGGCCAC
TGCACTCTA-3′, GAS5-SV-586-F, 5′- CCCAAGGAAG-
GATGAGAATAGC −3′ and GAS5-SV-586-R, 5′- CTCT
TTAGGACCTGGGAAGAAAC −3′. Amplified PCR prod-
ucts were analyzed on 3% agarose gel, then, they were ex-
cised from gels, purified (Qiagen Qiaquick® Gel Extraction
Kit) and sequenced (Microsynth, Balgach, Switzerland).
PCR bands were quantitated with densitometry using
Image J software (Version 1.42q, USA).
Flow cytometric analysis
The analysis of quiescent (G0) vs proliferative state (G1 or
S/G2/M) of cells was performed using Attune flow
cytometer (Applied Biosystems) and analyzed with the
Attune cytometric software v1.2.5 (Applied Biosystems)
accordingly to a previously described method [54]. Briefly,
cells were fixed with 70% ethanol and stained with FITC-
conjugated anti-Ki-67 (clone B56, BD Pharmingen) mono-
clonal antibody, accordingly to manufacturer instructions.
DNA was stained with DAPI (1 μg/ml) after 15 min diges-
tion with RNase A (10 μg/ml).
EdU incorporation assay
Cell cycle length was measured by Click iT™ EdU cell
proliferation assay kit (Molecular Probes, Invitrogen).
The EdU (5-ethynyl-2′-deoxyuridine) is a nucleoside
Renganathan et al. Molecular Cancer 2014, 13:119 Page 9 of 12
http://www.molecular-cancer.com/content/13/1/119
analog of thymidine that is incorporated into DNA only
during DNA synthesis allowing the visualization of newly
synthesized DNA [29]. To perform the assay shGAS5 cells
were plated on 4 well chambered slides and incubated at
37°C for overnight to 24 h. The cells were treated with
doxycycline for 72 hours with drug refreshment at 48 hrs.
At time intervals of 0, 6, 12 and 24 h, cells were treated
with 10 μM EdU and incubated at 37°C to ensure capture
of the majority of proliferating cells. Following EdU
addition, cells were fixed with ice cold 100% methanol for
20 min and permeabilised with ice cold acetone and
methanol (50:50) for 20 min followed by 0.2% triton X
100 for 10 min at room temperature. Incorporation of
EdU was observed by incubating fixed cells with 2% BSA
in PBS for 30 minutes and Alexa fluor 488 for a further
30 minutes under Cu(I)-catalyzed click reaction condi-
tions, as described by the manufacturer. Cells were
washed with PBS, and mounted with prolong GOLD anti-
fade agent with DAPI (Invitrogen) and visualized under
fluorescence microscopy.
RNA in-situ hybridization in MPM cells
To localize GAS5 lncRNA in MPM cells we performed
RNA ISH by using QuantiGene® ViewRNA cell assay kit
(Panomics Srl, Vignate-Milano, Italy). The oligonucleotide
probe was designed commercially using the human GAS5
sequence (accession number NM_002578). ShGAS5 cells
in 4-well chamber slides was treated at different concentra-
tions of HhAntag for 48 hours and permeabilized with
working detergent solution, and digested with protease at
1:8000 in PBS. The cells were hybridized for 3 hours at 40°
C with a cocktail of custom-designed QuantiGene View-
RNA probes against human GAS5 (type 6 probe), RNU2-1
(type 1 probe) and GAPDH (type 4 probe). Unhybridized
probes were flushed out with wash buffer and the hybrid-
ized probes were amplified with pre-amp hybridization for
1 hour at 40°C, followed by amp hybridization for 1 hour at
40°C. Label Probes (LP) targeting the GAS5, RNU2-1 and
GAPDH probe types were added for 30mins at 40°C. Cells
were washed with wash buffer and slides were mounted
with prolong GOLD anti-fade agent with DAPI and stored
at 4°C. The cells were imaged under CLSM Leica SP5 Res-
onant APD with confocal point-scanning and real optical
section (Centre for Microscopy and Image analysis, UZH,
Irchel). Twenty five Z stack steps per 0.5 μm at 40 ×magni-
fication imaging have been performed for each group with
zoom factor fixed as 2. The number of GAS5 lncRNA tran-
scripts inside the nucleus as well in single cell was quanti-
fied from z-stacked images of at least 100 randomly
selected cells on different fields for each condition using
the Spot detection module of Imaris 7.6.1 image analysis
software (Bitplane) with fixed spot size and adjusted thresh-
old. Intensity of fluorescent spots of GAS5 lncRNA in both
cell and nuclei was measured by filtering the spots with red
channel (RNU2-1) and this quantifies the spots which are
present in the nucleus of a cell. From the analysed images
the total number of fluorescent spots per cell or nucleus
was calculated with mean intensity of spots.
RNA in-situ hybridization in MPM tissue
Tissue sections of MPM patients were processed for
RNA-ISH by using QuantiGene® ViewRNA ISH tissue
assay kit (Panomics Srl, Vignate-Milano, Italy). Briefly, 3-
micron sections were deparaffinized, boiled in pre-
treatment solution (Affymetrix, Santa Clara, CA) for
5 minutes and digested with proteinase K for 10 minutes.
Sections were hybridized for 3 hours at 40°C with custom
designed QuantiGene ViewRNA probes against human
GAS5 (type 1 probe) and no probe as a control. After the
probe hybridization the slides were stored overnight in
supplied 1X storage buffer. Hybridized probes were then
amplified the following day as per protocol from Affyme-
trix using PreAmp and Amp molecules. Multiple Label
Probe oligonucleotides conjugated to alkaline phosphatase
(LP-AP Type 1) were then added and Fast Red Substrate
was used to produce signal (red dots). Slides were then
counterstained with Hematoxylin. Slides were scanned in
Zeiss Mirax Midi Slide Scanner equipped with fluorescence
scanner (Centre for Microscopy and Image analysis, UZH,
Irchel) and tissue sections were analysed by using Pannoro-
mic viewer 1.15.2 (3DHISTECH, Budapest, Hungary).
Immunohistochemistry
Deparaffinized sections were subjected to antigen retrieval
using Tris/EDTA (pH9.0) or sodium citrate (pH 6.0) buffer.
Following quenching in 0.3% H2O2 (20 min) and
permeabilization in 0.05% Saponin (5 min), blocking was
performed in 2% bovine serum albumin in PBS with 1%
horse serum (20 min; Vector Laboratories) at room
temperature. Sections were incubated with primary anti-
bodies (D2-40, 1:50; DAKO M3619, Baar, Switzerland and
Ki-67, 1:50; Abcam ab15580, Abcam, Cambridge, UK)
overnight at 4°C. Negative controls were incubated with
secondary biotinylated antibody only (Vectastain® Elite®
ABC Kit; Vector Laboratories, Servion, Switzerland). Sec-
tions were washed with PBS and incubated with sec-
ondary biotinylated antibody for 45 min at room
temperature. Staining was visualized using 3,3′-diami-
nobenzidine tetrahydrochloride (Sigma–Aldrich), coun-
terstained with Vector® hematoxilyn QS (Vector
Laboratories) and analyzed using a Zeiss Mirax Midi
Slide Scanner and image acquisition with a 3 CCD
color camera and Pannoromic viewer (3DHISTECH,
Budapest, Hungary).
Statistical analysis
Data are expressed as mean ± standard deviation of mul-
tiple experiments. Statistical analysis was performed using
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student t-test and Mann–Whitney tests and cell cycle
length was analyzed by linear regression and regression
slopes were evaluated by StatView 5.0.1 (SAS institute).
The comparison of GAS5 expression in PDPN low versus
PDPN high samples was performed by dichotomizing the
samples according to PDPN median relative expression
value. All statistical analysis was performed in GraphPad
Prism v5.03. Differences were considered statistically sig-
nificant at p < 0.05.
Additional files
Additional file 1: Figure S1. Profile of GAS5 lncRNA in different MPM
cell line. GAS5 lncRNA expression was analysed by qRT-PCR in 22 MPM
cell lines and in 7 normal mesothelial cell lines. Expression of GAS5 was
normalized to internal control histones relative to the mean expression of
GAS5 in normal mesothelial cells in culture according to –ΔΔCt method.
Additional file 2: Table S1. List of GAS5 alternative splice variants.
Additional file 3: Table S2. List of GAS5 alternative splice variants
detectable by RT-PCR primer sets.
Additional file 4: Figure S2. Different GAS5 alternative splice variants
are identified in MPM. A. Schematic representation of 3 alternative splice
variants of GAS5 expressed in MPM. Gray rectangles represent GAS5
exons, lines represent introns and white rectangle snoRNA. Arrows show
the location of primer sets. B, C and D. Semi-quantitative RT-PCR of tran-
scripts for GAS5 differentially expressed in the MPM primary cells and cell
lines selected for functional assays. The arrows point to the RT-PCR ampli-
con corresponding to the different products that can be obtained
(207 bp and 168 bp with exons 4 to 8 primer set; 281 bp and 242 bp
with exon 6–12 primer set; 233 bp with exon 3 together with SNORD76
(OTTHUMT00000090586, SV-586) . E. GAPDH was amplified from the
cDNA and was used for relative quantification.
Additional file 5: Figure S3. Cell cycle distribution of ZL55SPT cells
upon HhAntag induced growth arrest. HhAntag induced growth arrest
accumulates more cells at G0 state. Values are shown as mean ± SD from
three independent experiments. *; p < 0.05 compared to control.
Additional file 6: Figure S4. NVP-BEZ-235 increases GAS5 expression in
MPM primary cells ZL55SPT and SDM103T2 grown without serum in 3%
oxygen. Values are expressed as mean ± SD from three independent
experiments.
Additional file 7: Figure S5. Silencing of GAS5 with siRNA increases
glucocorticoid responsive genes. A. GAS5 lncRNA silencing increases the
expression of glucocorticoid responsive genes GILZ (B) and SGK1 (C).
Values are normalized with histones and shown as mean ± SD from four
independent experiments. *; p < 0.05.
Additional file 8: Figure S6. GAS5 expression in MPM. A. GAS5 expression
is higher in MPM tumor samples compared to non-tumoral tissue, *p < 0.0001
expression, Mann–Whitney test. B. Upper panel shows fluorescence in situ
hybridization of control and GAS5 and immunostaining of Ki-67 (ab15580,
Abcam) and lower panel shows the immunostaining of control and
podoplanin (D2-40, DAKOCytomation) and hematoxylin and eosin stained
tumor of another representative patient. Scale bar: 50 μm.
Additional file 9: Figure S7. GAS5 promoter in Chromosome 1 region
1q25.1. A screenshot of the UCSC Genome Browser shows GAS5 sharing
its promoter with ZBTB37.
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